about
Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trialalpha 2-Macroglobulin: a new component in the insulin-like growth factor/insulin-like growth factor binding protein-1 axis.What strategies are effective for exercise adherence in heart failure? A systematic review of controlled studies.Statins inhibit insulin-like growth factor action in first trimester placenta by altering insulin-like growth factor 1 receptor glycosylation.The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma.Type 2 diabetes whole-genome association study in four populations: the DiaGen consortiumThe Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease.Lifestyle factors and the metabolic syndrome in Schizophrenia: a cross-sectional study.Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?Glucose and insulin abnormalities in patients with heart failure.What can we learn from patients with heart failure about exercise adherence? A systematic review of qualitative papers.Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.Low insulin-like growth factor-II levels predict weight gain in normal weight subjects with type 2 diabetes.Protein kinetics in human endotoxaemia and their temporal relation to metabolic, endocrine and proinflammatory cytokine responses.Statins are detrimental to human placental development and function; use of statins during early pregnancy is inadvisable.Regulation of IGF bioavailability in pregnancy.Apposite insulin-like growth factor (IGF) receptor glycosylation is critical to the maintenance of vascular smooth muscle phenotype in the presence of factors promoting osteogenic differentiation and mineralization.Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways.Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations.Epidemiology of the insulin-like growth factor system in three ethnic groups.Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes.Evaluation of a bedside blood ketone sensor: the effects of acidosis, hyperglycaemia and acetoacetate on sensor performance.The unrecognized prevalence of chronic kidney disease in diabetes.Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial.Atorvastatin administration is associated with dose-related changes in IGF bioavailability.What influences physical activity in people with heart failure?: a qualitative study.The effect of atorvastatin on serum lipoproteins in acromegaly.Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.Marked differences in the IGF system that are associated with migration in comparable populations of Gujaratis living in Sandwell, UK, and Gujarat, India.Migration is associated with lower total, but not free testosterone levels in South Asian men.The influence of dietary intake on the insulin-like growth factor (IGF) system across three ethnic groups: a population-based study.Measurement of insulin-like growth factor-II in human plasma using a specific monoclonal antibody-based two-site immunoradiometric assay.Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome.Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.Inflammatory markers and growth in South Asian and European origin infants in Britain: the Manchester Children's Growth and Vascular Health Study.Modification of plasma insulin-like growth factors and binding proteins during oral contraceptive use and the normal menstrual cycle.Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).Telemedicine to improve glycaemic control: 3-year results from the Pro-Active Call Centre Treatment Support (PACCTS) trialThe use of eGFR and ACR to predict decline in renal function in people with diabetesGAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes
P50
Q28189788-924DB445-6737-4538-A0AC-FBDEB153FF02Q31008087-1F1D639C-8137-46DE-8AAB-F5456E50894CQ33897868-B8AB2807-3EE8-4F48-B573-FF57D1887D83Q34763832-B58DB661-3D4B-4654-AE86-9E458B27A67FQ35864591-AF4E394E-1E1C-495F-B952-6F33625318A2Q35946296-34BC92BD-F342-4F79-A7C9-64124800FD4FQ36023343-B9A3D167-BB83-4B3B-BB70-988F18B621D7Q37642973-0837FCF3-9D72-41DA-82AB-20EF2AA60017Q37783432-D43B2E07-1F83-45DD-83E9-6BD96E39BFD1Q37801130-8CC407C5-344F-4841-9406-008F96B6E698Q37870916-79A05767-5305-436B-91EF-2805BA79F69DQ40048314-14C68D64-7015-42DA-A0B5-5B77BDD629FFQ40354898-0FF391FD-138E-4D67-B5DC-1595116FBABEQ41251858-81C3FBEB-9E6F-4C0E-AAFA-56EB013A280BQ42386134-22DE0C03-D370-493E-9DAF-40AE70BA8ED1Q42497840-4AAF044E-8FF2-464C-A3D8-C8B64C5FDA46Q42728392-AFB2F1BC-5428-4E51-A5DF-AB789F52F3E3Q42827445-A96D3984-66BE-4884-A1B9-A8E31969ADE5Q43585451-8F2AA0D1-79F5-4315-94D9-21256BCC87EFQ43732348-6A92B1D8-8F38-4DF3-A107-7E4BFDA37190Q44081042-5BCD09F1-CE41-419A-9C2E-8CFE7011EB7EQ44946406-E13D484B-1699-40F3-A4AB-646AC02A6F31Q44946567-8C4D38E4-27A7-4F66-B256-7CC39E26FDAEQ45199362-AEB44192-DF0E-4681-913B-8B809162258FQ45868574-2FC1DD91-E45E-43AF-A732-0C831C144AA8Q45879723-ADC9F9E8-34C1-486D-9CF1-60CDE5C213C1Q46534865-55EA3B02-47C5-442E-9E9A-8C060D7CC83CQ46600441-6656B84F-209F-401D-B923-40F094E348B3Q46616695-839B2CB0-310A-4353-8233-40649A3C5D3FQ46978159-5514E5AF-B4FC-414E-85DB-6883A08FA89DQ47564354-6C94B7B6-29DA-4FCD-AA65-10B7D32720A9Q47566811-A7566981-2879-420C-8DA2-B96A78020AD7Q47591447-2D64B52D-A3C8-446A-97DA-574D67AACD9FQ47607188-0E04F3CB-C294-44F5-887E-E934874449B1Q47809515-2C805548-8F81-4A6F-8C69-62176616CF3AQ51564795-9995523D-8277-4D6B-B270-AE832C05927FQ55053682-120B455B-6FAA-4AB0-99F5-1DCAEB61182DQ58618911-0E92BB4E-8C04-4AE0-BA1F-F0BE39EF69DFQ58851916-7DF68FA1-8CB9-4A0C-AE55-0AF952D9B35CQ62000550-D3DA24E5-6404-46C3-AD26-10A1094502C1
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Martin Gibson
@ast
Martin Gibson
@en
Martin Gibson
@es
Martin Gibson
@nl
type
label
Martin Gibson
@ast
Martin Gibson
@en
Martin Gibson
@es
Martin Gibson
@nl
prefLabel
Martin Gibson
@ast
Martin Gibson
@en
Martin Gibson
@es
Martin Gibson
@nl
P1153
55186112500
56537739400
P31
P496
0000-0002-1331-1524